GV 2017, L.P. 13D and 13G filings for Verve Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-11 4:16 pm Purchase |
2023-12-01 | 13G | Verve Therapeutics, Inc. VERV |
GV 2017, L.P. | 12,349,086 15.400% |
1,800,000 (+17.06%) |
Filing |
| 2023-02-10 4:05 pm Sale |
2022-12-31 | 13G | Verve Therapeutics, Inc. VERV |
GV 2017, L.P. | 10,549,086 17.100% |
-424,925 (-3.87%) |
Filing |
| 2022-02-14 5:15 pm Purchase |
2021-12-31 | 13G | Verve Therapeutics, Inc. VERV |
GV 2017, L.P. | 10,974,011 22.780% |
10,974,011 (New Position) |
Filing |